Spots Global Cancer Trial Database for autologous stem cell transplant
Every month we try and update this database with for autologous stem cell transplant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant | NCT01416246 | Multiple Myelom... | Fractionated St... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis | NCT00323518 | Oral Mucositis Stomatitis | velafermin placebo | 18 Years - | Celldex Therapeutics | |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | NCT05827016 | Multiple Myelom... | Iberdomide Lenalidomide | 18 Years - | Bristol-Myers Squibb | |
| ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma | NCT00144807 | Diffuse Large C... | rituximab doxorubicin cyclophosphamid... autologous stem... | 18 Years - 59 Years | Lymphoma Study Association | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | NCT00661544 | Multiple Myelom... Stem Cell Trans... | Arsenic Trioxid... Melphalan Ascorbic Acid | - 70 Years | M.D. Anderson Cancer Center | |
| Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | NCT05464329 | Diffuse Large B... High-grade B-ce... Transformed B-C... Follicular Lymp... | Mosunetuzumab DHAX ICE | 18 Years - | Washington University School of Medicine | |
| Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | NCT03948035 | Newly Diagnosed... | Elotuzumab Carfilzomib Lenalidomide Dexamethasone autologous stem... | 18 Years - 70 Years | Wuerzburg University Hospital | |
| Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | NCT02655458 | Multiple Myelom... | Elotuzumab Lenalidomide autologous PBMC... ASCT | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant | NCT02181413 | Multiple Myelom... Autologous Stem... | Ixazomib Citrat... Placebo | 18 Years - | Takeda | |
| Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM | NCT04653246 | Multiple Myelom... Newly Diagnosed... Autologous Stem... | Isatuximab Lenalidomide Bortezomib Inje... Dexamethasone | 75 Years - | Dana-Farber Cancer Institute | |
| A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | NCT02572167 | Hodgkin Lymphom... | brentuximab ved... nivolumab | 18 Years - | Seagen Inc. | |
| MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | NCT01380145 | Multiple Myelom... | recMAGE-A3 Prot... | 18 Years - | Ludwig Institute for Cancer Research | |
| Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions | NCT00660166 | Lymphoma Myeloma Leukemia | NK-Cell Infusio... | 13 Years - 70 Years | Tufts Medical Center | |
| Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | NCT05665140 | Newly Diagnosed... | Isatuximab Lenalidomide Bortezomib Dexamethasone autologous stem... | 18 Years - 70 Years | University Hopsital Schleswig Holstein Campus Lübeck | |
| Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | NCT03948035 | Newly Diagnosed... | Elotuzumab Carfilzomib Lenalidomide Dexamethasone autologous stem... | 18 Years - 70 Years | Wuerzburg University Hospital | |
| Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma | NCT01045460 | Multiple Myelom... | Activated marro... Allogeneic Myel... Cyclophosphamid... Filgrastim Leukapheresis Melphalan Autologous stem... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70. | NCT05947136 | Multiple Myelom... Complication | Interpretation ... Explaining dete... Early medical c... Transmission of... | 18 Years - 70 Years | Centre Leon Berard | |
| Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM | NCT04653246 | Multiple Myelom... Newly Diagnosed... Autologous Stem... | Isatuximab Lenalidomide Bortezomib Inje... Dexamethasone | 75 Years - | Dana-Farber Cancer Institute | |
| Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma | NCT01014208 | Lymphoma, Large... | OFATUMUMAB + DH... RITUXIMAB + DHA... | 18 Years - | GlaxoSmithKline | |
| Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma Patients | NCT04783038 | Multiple Myelom... Autologous Stem... | Distance Reiki Sham distance R... | 18 Years - | Mayo Clinic | |
| Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma | NCT00169169 | CD20-Positive L... | ACVBP ACE rituximab Autologous stem... | 18 Years - 59 Years | Lymphoma Study Association | |
| Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | NCT05706766 | Multiple Myelom... Stem Cell Trans... | PARE Waitlist Contro... | 18 Years - | Dana-Farber Cancer Institute | |
| Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant | NCT01540175 | Solid Tumor Brain Tumor Lymphoma | Blood samples o... | - 21 Years | St. Jude Children's Research Hospital | |
| Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | NCT00992446 | Adult Diffuse L... B-Cell Non-Hodg... Follicular Lymp... Mantle Cell Lym... Non-Hodgkin Lym... T-Cell Non-Hodg... | Autologous Hema... Bortezomib Carmustine Cytarabine Etoposide Melphalan Rituximab Vorinostat | 18 Years - | Fred Hutchinson Cancer Center | |
| The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma | NCT01235793 | B-Cell Lymphoma... | Temozolomide | 18 Years - 75 Years | Cedars-Sinai Medical Center | |
| Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma Patients | NCT04783038 | Multiple Myelom... Autologous Stem... | Distance Reiki Sham distance R... | 18 Years - | Mayo Clinic | |
| A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant | NCT00515138 | Lymphoma, B-Cel... | Rituximab, Ifos... | 18 Years - 70 Years | University of California, San Francisco | |
| Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | NCT05464329 | Diffuse Large B... High-grade B-ce... Transformed B-C... Follicular Lymp... | Mosunetuzumab DHAX ICE | 18 Years - | Washington University School of Medicine | |
| Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | NCT03072771 | Diffuse Large B... | Blinatumomab Autologous stem... Carmustine Etoposide Cytarabine Melphalan Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma | NCT02331368 | Multiple Myelom... | Autologous Stem... Melphalan Lenalidomide MK-3475 | 18 Years - 75 Years | University of Michigan Rogel Cancer Center | |
| Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma Patients | NCT04783038 | Multiple Myelom... Autologous Stem... | Distance Reiki Sham distance R... | 18 Years - | Mayo Clinic | |
| Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma | NCT00867087 | Lymphoma, B-Cel... | inotuzumab ozog... rituximab | 18 Years - | Pfizer | |
| High Dose Chemotherapy and Autologous Transplant for Neuroblastoma | NCT01526603 | Neuroblastoma | Carboplatin Autologous stem... Granulocyte col... Radiation thera... Isotretinoin (1... Melphalan Etoposide | - 30 Years | Masonic Cancer Center, University of Minnesota | |
| Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma | NCT02728531 | Mantle Cell Lym... | Bendamustine Rituximab Cytarabine Pegfilgrastim Leukapheresis Filgrastim Autologous stem... | 18 Years - 65 Years | Washington University School of Medicine | |
| Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | NCT00992446 | Adult Diffuse L... B-Cell Non-Hodg... Follicular Lymp... Mantle Cell Lym... Non-Hodgkin Lym... T-Cell Non-Hodg... | Autologous Hema... Bortezomib Carmustine Cytarabine Etoposide Melphalan Rituximab Vorinostat | 18 Years - | Fred Hutchinson Cancer Center | |
| Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma | NCT00169143 | Untreated CD20-... | Rituximab + ACV... Autologous stem... | 18 Years - 61 Years | Lymphoma Study Association | |
| A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | NCT02572167 | Hodgkin Lymphom... | brentuximab ved... nivolumab | 18 Years - | Seagen Inc. | |
| Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | NCT01849783 | Extramedullary ... Isolated Plasma... Light Chain Dep... Primary Systemi... Stage I Multipl... Stage II Multip... Stage III Multi... | dexamethasone cisplatin doxorubicin cyclophosphamid... etoposide bortezomib thalidomide melphalan autologous stem... | 65 Years - 85 Years | University of Iowa | |
| Autologous and Allogeneic Transplant for Relapsed Lymphoma | NCT00802113 | Non-Hodgkin's L... Hodgkins Diseas... | Fludarabine Busulfan Anti-Thymocyte ... | - 55 Years | Columbia University | |
| Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | NCT01849783 | Extramedullary ... Isolated Plasma... Light Chain Dep... Primary Systemi... Stage I Multipl... Stage II Multip... Stage III Multi... | dexamethasone cisplatin doxorubicin cyclophosphamid... etoposide bortezomib thalidomide melphalan autologous stem... | 65 Years - 85 Years | University of Iowa | |
| Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma | NCT00867087 | Lymphoma, B-Cel... | inotuzumab ozog... rituximab | 18 Years - | Pfizer | |
| Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT | NCT02992223 | Refractory B-Ce... Recurrent B-Cel... | 19 Years - | Azienda Ospedaliera Città della Salute e della Scienza di Torino | ||
| Rituximab Maintenance After Autologous Transplantation | NCT01103388 | Non-Hodgkin's L... | Rituximab | - | M.D. Anderson Cancer Center | |
| Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma | NCT00867087 | Lymphoma, B-Cel... | inotuzumab ozog... rituximab | 18 Years - | Pfizer | |
| Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction | NCT03165292 | Very High Risk ... | mIBG Topotecan Thiotepa Autologous stem... | - | Gustave Roussy, Cancer Campus, Grand Paris | |
| PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70. | NCT05947136 | Multiple Myelom... Complication | Interpretation ... Explaining dete... Early medical c... Transmission of... | 18 Years - 70 Years | Centre Leon Berard | |
| Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma | NCT02168101 | Multiple Myelom... | MLN9708 | 18 Years - 70 Years | SCRI Development Innovations, LLC | |
| Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | NCT00992446 | Adult Diffuse L... B-Cell Non-Hodg... Follicular Lymp... Mantle Cell Lym... Non-Hodgkin Lym... T-Cell Non-Hodg... | Autologous Hema... Bortezomib Carmustine Cytarabine Etoposide Melphalan Rituximab Vorinostat | 18 Years - | Fred Hutchinson Cancer Center | |
| Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma | NCT00916058 | Multiple Myelom... | Bendamustine Melphalan Bendamustine Bendamustine Bendamustine Bendamustine Bendamustine | 18 Years - | Weill Medical College of Cornell University | |
| Phase I, Dose Escalation Study of Decitabine | NCT02264873 | Leukemia, Lymph... Leukemia, Myelo... Hematopoetic My... | Decitabine | 1 Year - 30 Years | University of Florida | |
| A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant | NCT02181413 | Multiple Myelom... Autologous Stem... | Ixazomib Citrat... Placebo | 18 Years - | Takeda | |
| This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. | NCT00720603 | Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... | Plerixafor | 18 Years - | Sanofi | |
| ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma | NCT00169130 | Lymphoma, Large... | doxorubicin cyclophosphamid... Autologous stem... | 18 Years - 60 Years | Lymphoma Study Association | |
| Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | NCT00661544 | Multiple Myelom... Stem Cell Trans... | Arsenic Trioxid... Melphalan Ascorbic Acid | - 70 Years | M.D. Anderson Cancer Center | |
| Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL). | NCT01296256 | Bendamustine Conditioning Th... Autologous Stem... Aggressive Non ... | Bendamustine-EA... | 18 Years - 70 Years | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | NCT05665140 | Newly Diagnosed... | Isatuximab Lenalidomide Bortezomib Dexamethasone autologous stem... | 18 Years - 70 Years | University Hopsital Schleswig Holstein Campus Lübeck | |
| Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | NCT02655458 | Multiple Myelom... | Elotuzumab Lenalidomide autologous PBMC... ASCT | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant | NCT05271630 | Multiple Myelom... | Autologous Stem... Immunomodulator... Proteasome Inhi... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | NCT06377540 | Autologous Stem... Classic Hodgkin... | Pembrolizumab Autologous stem... Carmustine Etoposide Cytarabine Melphalan | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | NCT06377540 | Autologous Stem... Classic Hodgkin... | Pembrolizumab Autologous stem... Carmustine Etoposide Cytarabine Melphalan | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant | NCT01416246 | Multiple Myelom... | Fractionated St... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 | NCT01208662 | Multiple Myelom... | Lenalidomide Bortezomib Dexamethasone Autologous Stem... | 18 Years - 65 Years | Dana-Farber Cancer Institute | |
| Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma | NCT06140966 | Multiple Myelom... Primary Plasma ... Extramedullary ... | Daratumumab Carfilzomib Lenalidomide Dexamethasone Cisplatin epirubicin Cyclophosphamid... Etoposide Melphalan ASCT bortezomib | 18 Years - 70 Years | Wuhan Union Hospital, China | |
| High Dose Chemotherapy and Autologous Transplant for Neuroblastoma | NCT01526603 | Neuroblastoma | Carboplatin Autologous stem... Granulocyte col... Radiation thera... Isotretinoin (1... Melphalan Etoposide | - 30 Years | Masonic Cancer Center, University of Minnesota | |
| Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma | NCT02168101 | Multiple Myelom... | MLN9708 | 18 Years - 70 Years | SCRI Development Innovations, LLC | |
| High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma | NCT01182415 | Non-Hodgkin's L... CNS Lymphoma | Autologous stem... High-dose chemo... | 18 Years - 75 Years | Massachusetts General Hospital | |
| Autologous and Allogeneic Transplant for Relapsed Lymphoma | NCT00802113 | Non-Hodgkin's L... Hodgkins Diseas... | Fludarabine Busulfan Anti-Thymocyte ... | - 55 Years | Columbia University | |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | NCT05827016 | Multiple Myelom... | Iberdomide Lenalidomide | 18 Years - | Bristol-Myers Squibb | |
| A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant | NCT00515138 | Lymphoma, B-Cel... | Rituximab, Ifos... | 18 Years - 70 Years | University of California, San Francisco | |
| Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma | NCT00948922 | Multiple Myelom... | Bortezomib Melphalan Autologous Stem... Fludarabine Allogeneic Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | NCT05665140 | Newly Diagnosed... | Isatuximab Lenalidomide Bortezomib Dexamethasone autologous stem... | 18 Years - 70 Years | University Hopsital Schleswig Holstein Campus Lübeck | |
| Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma | NCT00948922 | Multiple Myelom... | Bortezomib Melphalan Autologous Stem... Fludarabine Allogeneic Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden | NCT00651937 | Multiple Myelom... Primary Amyloid... | Melphalan Stem Cell Infus... Questionnaires Granulocyte-col... Apheresis | 60 Years - | M.D. Anderson Cancer Center | |
| Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma | NCT00948922 | Multiple Myelom... | Bortezomib Melphalan Autologous Stem... Fludarabine Allogeneic Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma | NCT02274519 | Multiple Myelom... Plasma Cell Dis... | Tai Chi Education | 18 Years - | Mayo Clinic | |
| Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | NCT03948035 | Newly Diagnosed... | Elotuzumab Carfilzomib Lenalidomide Dexamethasone autologous stem... | 18 Years - 70 Years | Wuerzburg University Hospital | |
| Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma | NCT00916058 | Multiple Myelom... | Bendamustine Melphalan Bendamustine Bendamustine Bendamustine Bendamustine Bendamustine | 18 Years - | Weill Medical College of Cornell University | |
| A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL). | NCT00301288 | Non-Hodgkins Ly... | Autologous stem... | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma | NCT00572013 | Lymphoma | Rituxan BEAM Autologous stem... | 19 Years - | University of Nebraska |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
